Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Histostem to acquire Stem Cell Therapy
The definitive agreement calls for closing of the acquisition by April 30, 2008, or sooner if the investment bankers working on the financial aspects of the transaction are
The definitive agreement calls for closing of the acquisition by April 30, 2008, or sooner if the investment bankers working on the financial aspects of the transaction are
In addition, Symbicort has provided a similar bronchodilatory response to albuterol. Bronchodilatory response is defined as the mean time to achieve improvement in lung function. In both studies,
The private equity investment is being led by Forward Ventures, Jafco, and Novartis Venture Fund, with significant participation from Fidelity Biosciences and MedImmune Ventures. Additional investors include Athenian
The multi-center study observed the effect of Cinryze on the frequency of hereditary angioedema (HAE) attacks. The primary endpoint was met with a 52% reduction in the number
Based on the clinical trial data, the investigators concluded that Angiotech’s 5-Fluorouracil-coated (5-FU) Central Venous Catheter (CVC) met the primary endpoint of the study: non-inferior in its ability
Pursuant to the settlement agreement, the company has expressly denied engaging in any wrongful conduct. The settlement calls for payment by the company of $36.7 million, plus approximately
The Phase I single ascending dose, double blind placebo controlled randomized study involved 56 healthy volunteers who received the drug in eight escalating dose cohorts. All doses were
The restructuring will primarily affect the company’s research and administrative functions. As a result of the restructuring, most research programs will be placed on hold. The company may
Blopress is an angiotensin II receptor blocker (ARB) and hydrochlorothiazide is classified as a thiazide diuretic and lowers the blood pressure by increasing the flow of urine, which
MedImmune is currently evaluating MEDI-528 in patients with asthma in a series of Phase II clinical trials. The goal of the current Phase IIa trial is to assess